AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Crane NXT today, you need to believe in a steady, execution-led story rather than a dramatic turnaround. The company has been growing sales, raising full-year guidance and lifting its dividend, but margins have come under pressure and debt is still on the high side, all under a relatively new management team and board. The near term catalyst is clear: the upcoming Q4 2025 earnings release and any update to the outlook, especially around earnings growth and balance sheet priorities. The recent U.S. decision to back away from 10% tariffs on European allies helps at the margin by easing one external risk, which partly explains the stock’s relief bounce, but it does not fundamentally change the bigger issues investors are watching.
However, one operational risk could matter more than the tariff headlines for shareholders. Despite retreating, Crane NXT's shares might still be trading 24% above their fair value. Discover the potential downside here.Explore 4 other fair value estimates on Crane NXT - why the stock might be worth just $49.27!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Contact Us
Contact Number : +852 3852 8500
English